Synopsis
Select and monitor prostate-directed medicines using symptom goals, progression risk, formulation-specific dosing and clinically important adverse effects.
- Alpha blockers relax outlet smooth muscle and can relieve symptoms before a measurable change in gland size.
- Five-alpha-reductase inhibitors reduce androgen-driven enlargement and lower future retention or surgery risk in appropriately selected men.
- Combination therapy can address both goals but increases treatment burden and exposure to adverse effects.
Reasoning priorities
Specify what treatment is intended to improve and create a meaningful comparison.
Use a validated symptom measure and one practical goal, such as completing a journey without repeated stops. Ask about baseline erection, ejaculation and mood to distinguish pre-existing problems from a new temporal association with treatment.
Worked reasoning
A 73-year-old man with a 60 ml prostate has persistent bothersome LUTS.
- Assessment finds IPSS 21, normal standing blood pressure, no concerning cancer findings and no renal complication. He wants better flow now and a lower chance of retention over coming years.
- After counselling, he starts a Zentiva tamsulosin 400 microgram prolonged-release capsule orally once daily after breakfast, alongside a Milpharm finasteride 5 mg film-coated tablet orally once daily with or without food; both are swallowed whole. The prescriber records baseline PSA, sexual function and mood and checks for an existing combination product to avoid duplication.
- At five weeks IPSS is 14 and he reports easier voiding without dizziness. This early change fits alpha-blocker action; it is too soon to call the tissue-directed component ineffective.
- At six months symptoms remain improved, treatment is tolerated and PSA has fallen to a new baseline. The clinician explains that future rises still require assessment rather than being dismissed because the absolute number appears normal.
- Verification includes medication adherence, patient-defined benefit and absence of retention or renal deterioration. Continuing combination treatment is a shared decision rather than a prescription renewed indefinitely without review.
Key medicines
Tamsulosin hydrochloride Zentiva prolonged-release capsule400 micrograms by mouth once daily after breakfast or the first daily meal; swallow whole without crushing. Use this daily dose, reviewing benefit at 4–6 weeks.Contraindicated with orthostatic hypotension history or severe hepatic insufficiency. No routine renal adjustment; caution if creatinine clearance is below 10 ml/min. Avoid initiation before scheduled cataract or glaucoma surgery and disclose previous use. Strong CYP3A4 inhibitors must not accompany this treatment in a poor CYP2D6 metaboliser; other strong or moderate CYP3A4 combinations require caution.
Finasteride 5 mg film-coated tablet5 mg orally once daily with or without food; do not crush or divide. Assess benefit after at least six months and continue long term if the indication remains.No renal dose reduction is required; hepatic data are limited. Explain persistent sexual symptoms, psychiatric effects and prompt medical contact for mood changes. Pregnant people must avoid broken tablets. After six months, double PSA for comparison with untreated ranges and investigate sustained rises.